<DOC>
	<DOCNO>NCT01086423</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity reactogenicity Infanrix-IPV/Hib™ vaccine administer healthy Chinese infant 2 , 3 4 3 , 4 5 month age .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' Infanrix-IPV+Hib™ Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female infant , include , 60 90 day age time first study visit . Born gestation period 36 42 week , inclusive . Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . Written inform consent obtain parent ( ) LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Child care . Chronic administration immunosuppressant immunemodifying drug since birth . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration vaccine foreseen study protocol within 30 day prior vaccination , plan administration study period , exception hepatitis B vaccine . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Evidence previous intercurrent diphtheria , tetanus , pertussis , poliomyelitis and/or Haemophilus influenzae type b ( Hib ) disease vaccination . History seizures progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction hypersensitivity likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . The following condition temporary selflimiting subject may vaccinate condition resolve exclusion criterion meet : • Current febrile illness axillary temperature &gt; 37.0°C moderate severe illness within 24 hour study vaccine administration .</criteria>
	<gender>All</gender>
	<minimum_age>60 Days</minimum_age>
	<maximum_age>90 Days</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Infanrix-IPV+Hib</keyword>
</DOC>